Literature DB >> 15808152

Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration.

Ruxandra Hera1, Michelle Keramidas, Michel Peoc'h, Michel Mouillon, Jean-Paul Romanet, Jean-Jacques Feige.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) and angiopoietins are key regulators of angiogenesis. The purpose of this study was to measure mRNA levels of these factors and of their receptors in surgically excised subfoveal membranes from patients with age-related macular degeneration (AMD) and to evaluate their relevance as prognostic markers of postsurgical recurrence of choroidal neovascularization (CNV).
DESIGN: Prospective observational case series.
METHODS: setting: Institutional. study population: In a prospective series of 24 patients (aged 51 to 91 years) with classic CNV of AMD diagnosed less than 6 months previously, 24 subfoveal membranes (one eye per patient) were surgically removed and collected. Thirteen patients underwent treatment for recurrence of CNV within 6 months of surgery. main outcome measures: Four 8-mu sections were prepared from each membrane for immunohistochemical determination of vascular density (CD31 immunostaining). The remaining tissue was used for preparation of total RNA. The levels of VEGF-A, VEGF-R1, VEGF-R2, neuropilin-1, angiopoietin-1, angiopoietin-2, Tie-2, and hypoxanthine phosphoribosyltransferase mRNAs were determined by real-time reverse-transcriptase polymerase chain reaction.
RESULTS: Vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 appeared to be expressed to variable levels in most samples, whereas Tie-2, VEGF-R1, and VEGF-R2 were undetectable. Low levels of VEGF expression correlated with postsurgical recurrence of CNV (P = .07). Angiopoietin-1 and angiopoietin-2 levels did not predict recurrence (P > .1).
CONCLUSION: The results indicate that at the time of surgical excision, subfoveal membranes express angiopoietin-1, VEGF, and, to a lesser degree, angiopoietin-2. Because CNV appears to recur less often in membranes expressing high levels of VEGF, we hypothesize that VEGF acts as a stabilizer of neovessels at this stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808152     DOI: 10.1016/j.ajo.2004.11.064

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  20 in total

Review 1.  Glycobiology of ocular angiogenesis.

Authors:  Anna I Markowska; Zhiyi Cao; Noorjahan Panjwani
Journal:  Glycobiology       Date:  2014-08-08       Impact factor: 4.313

2.  Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.

Authors:  Katerina Hufendiek; Karsten Hufendiek; Georgios Panagakis; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2012-04-18       Impact factor: 2.031

Review 3.  Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.

Authors:  Claudio Campa; Ciro Costagliola; Carlo Incorvaia; Carl Sheridan; Francesco Semeraro; Katia De Nadai; Adolfo Sebastiani; Francesco Parmeggiani
Journal:  Mediators Inflamm       Date:  2010-08-25       Impact factor: 4.711

4.  Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration.

Authors:  Maria-Andreea Gamulescu; Viola Radeck; Bruno Lustinger; Bianca Fink; Horst Helbig
Journal:  Int Ophthalmol       Date:  2009-07-26       Impact factor: 2.031

5.  Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.

Authors:  Jun Li; Han Zhang; Peng Sun; Feng Gu; Zhe-Li Liu
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

6.  Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples.

Authors:  Sankarathi Balaiya; Sandeep Grover; Ravi K Murthy; Kakarla V Chalam
Journal:  Clin Ophthalmol       Date:  2011-01-11

Review 7.  Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases.

Authors:  Maria H Madeira; Raquel Boia; Paulo F Santos; António F Ambrósio; Ana R Santiago
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

8.  Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration.

Authors:  Kai Fang; Jun Tian; Xueying Qing; Shuai Li; Jing Hou; Juan Li; Wenzhen Yu; Dafang Chen; Yonghua Hu; Xiaoxin Li
Journal:  J Ophthalmol       Date:  2013-08-28       Impact factor: 1.909

9.  Adeno-associated virus type 8 vector-mediated expression of siRNA targeting vascular endothelial growth factor efficiently inhibits neovascularization in a murine choroidal neovascularization model.

Authors:  Tsutomu Igarashi; Noriko Miyake; Chiaki Fujimoto; Chiemi Yaguchi; Osamu Iijima; Takashi Shimada; Hiroshi Takahashi; Koichi Miyake
Journal:  Mol Vis       Date:  2014-04-11       Impact factor: 2.367

10.  Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Authors:  Deepika Malik; Mohamed Tarek; Javier Caceres del Carpio; Claudio Ramirez; David Boyer; M Cristina Kenney; Baruch D Kuppermann
Journal:  Br J Ophthalmol       Date:  2014-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.